Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER
- PMID: 20889601
- DOI: 10.3899/jrheum.100208
Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER
Abstract
Objective: To evaluate the efficacy and safety of initial combination treatment with adalimumab (ADA) and methotrexate (MTX) versus monotherapy with ADA or MTX during an open-label extension of PREMIER.
Methods: Patients with early rheumatoid arthritis (RA) received blinded ADA plus MTX, ADA alone, or MTX alone for 2 years in PREMIER. At Year 2, patients could enroll in an open-label extension and receive ADA monotherapy; MTX could be added at the investigator's discretion. Longterm efficacy results are presented as observed data.
Results: In the open-label period, 497 of the original 799 randomized patients had ≥ 1 dose of ADA (by original randomization: ADA plus MTX, n = 183; ADA, n = 159; MTX, n = 155). In the completers cohort [patients with available Year-5 ACR responses and modified total Sharp scores (mTSS)], the Year-5 mean change from baseline in mTSS for the ADA+MTX arm (n = 124) was 2.9, compared with 8.7 and 9.7 in the ADA (n = 115) and MTX (n = 115) arms. Comprehensive disease remission, defined as the combination of DAS28 remission, normal function (Health Assessment Questionnaire ≤ 0.5), and radiographic nonprogression (ΔmTSS ≤ 0.5), was achieved by more patients in the initial ADA+MTX arm (35%) than in the ADA (13%) or MTX (14%) arms.
Conclusion: Initial combination treatment with ADA plus MTX, followed by open-label ADA, led to better longterm clinical, functional, and radiographic outcomes than either initial ADA or MTX monotherapy during 5 years of treatment.
Similar articles
-
Longterm effect of delaying combination therapy with tumor necrosis factor inhibitor in patients with aggressive early rheumatoid arthritis: 10-year efficacy and safety of adalimumab from the randomized controlled PREMIER trial with open-label extension.J Rheumatol. 2014 Jan;41(1):5-14. doi: 10.3899/jrheum.130543. Epub 2013 Nov 15. J Rheumatol. 2014. PMID: 24241487 Clinical Trial.
-
The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.Arthritis Rheum. 2006 Jan;54(1):26-37. doi: 10.1002/art.21519. Arthritis Rheum. 2006. PMID: 16385520 Clinical Trial.
-
Analysis of integrated radiographic data from two long-term, open-label extension studies of adalimumab for the treatment of rheumatoid arthritis.Arthritis Care Res (Hoboken). 2015 Feb;67(2):180-6. doi: 10.1002/acr.22426. Arthritis Care Res (Hoboken). 2015. PMID: 25073879 Clinical Trial.
-
[Adalimumab (Humira)--efficacy in rheumatoid arthritis treatment with particular reference to working ability].Reumatizam. 2008;55(2):62-7. Reumatizam. 2008. PMID: 19024278 Review. Croatian.
-
[Biologic therapy with anti-TNFα in rheumathoid arthritis].Reumatismo. 2005;57(4 Suppl):17-21. Reumatismo. 2005. PMID: 16385351 Review. Italian.
Cited by
-
Recapturing adequate control of psoriasis by additional immunosuppressive agents alongside ustekinumab.JAAD Case Rep. 2016 Aug 8;2(4):310-4. doi: 10.1016/j.jdcr.2016.05.004. eCollection 2016 Jul. JAAD Case Rep. 2016. PMID: 27547809 Free PMC article. No abstract available.
-
Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.Curr Rheumatol Rep. 2014 May;16(5):417. doi: 10.1007/s11926-014-0417-8. Curr Rheumatol Rep. 2014. PMID: 24619653 Review.
-
Rheumatoid arthritis treatment: the earlier the better to prevent joint damage.RMD Open. 2015 Aug 15;1(Suppl 1):e000057. doi: 10.1136/rmdopen-2015-000057. eCollection 2015. RMD Open. 2015. PMID: 26557378 Free PMC article. Review.
-
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs.Drugs. 2024 Aug;84(8):877-894. doi: 10.1007/s40265-024-02059-8. Epub 2024 Jul 1. Drugs. 2024. PMID: 38949688 Free PMC article. Review.
-
Screening for sarcopenia and obesity by measuring thigh muscle and fat thickness by ultrasound in patients with rheumatoid arthritis.Osteoporos Sarcopenia. 2021 Jun;7(2):81-87. doi: 10.1016/j.afos.2021.06.002. Epub 2021 Jun 16. Osteoporos Sarcopenia. 2021. PMID: 34278004 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials